Modified Citrus Pectin holds effective against prostate cancer
July 4th, 2010 Posted in hormone therapyA research team at Columbia University evaluated the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines.
The results show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner. According to teal leader, study findings clearly demonstrate that MCP possesses anti-prostate cancer properties in both androgen-dependent (hormonal sensitive) and androgen-independent (hormonal resistant) prostate cancer cells. Researchers results strongly suggest that MCP can be a promising chemopreventive and therapeutic agent against prostate cancer
All findings are reported by lead researcher Dr. Aaron Katz in the most recent publication of Integrative Cancer Therapies.